6505--Radiopharmaceutical - Pylarify
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Department of Veterans Affairs has awarded a firm fixed-price delivery order to Progenics Pharmaceuticals, Inc., a certified small business, for the procurement of Pylarify (piflufolastat F-18) injections. This radiopharmaceutical is used for PET/CT imaging to diagnose metastatic prostate cancer at the DC VAMC Nuclear Medicine Department. The contract was awarded on a sole source basis under FAR 8.4 and GSAM/R 538.7104-3(b) because Pylarify is a proprietary, FDA-approved product with a unique 110-minute half-life that provides superior scheduling flexibility and reduced dose degradation compared to available alternatives. The agreement consists of a base period from January 1, 2026, to December 31, 2026, with four subsequent one-year option periods extending through December 31, 2030. The base period award is valued at $1,811,577.44 for an estimated 502 units, with a total estimated contract value of $9,057,887.20 including all option years. Performance takes place at the DC VAMC in Washington, DC, and the procurement is managed under Federal Supply Schedule contract 36F79725D0093, SIN 42-2A.
General Info
Contract Value
$1,811,577.44Place of Performance
MDSet-Aside
Award Issued Date
Timeline
Organization & Contact Information
Full Description
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Veterans Affairs → 245-NETWORK Contract Office 5 (36C245)
Same awarding agency
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
